Empagliflozin

Healio and Cardiology Today compiled the most-read cardiology news of February 2022.

The FDA recently expanded the indication for the SGLT2 inhibitor empagliflozin to reduce the risk for cardiovascular death and heart failure hospitalization in adults with heart failure with reduced or preserved ejection fraction.

The FDA approved an expanded indication for the SGLT2 inhibitor empagliflozin to reduce the risk for CV death and HF hospitalization in adults with HF with reduced or preserved ejection fraction, according to an agency press release.

For commercial insurers and Medicare, it may be cost-effective to add empagliflozin to the standard of care treatment for patients with diabetic kidney disease, according to data published in the American Journal of Kidney Diseases.

Biykem Bozkurt, MD, PhD, the Mary and Gordon Cain Chair and Professor of Medicine at Baylor College of Medicine, spoke with Healio about results from trials on HF presented at the American Heart Association Scientific Sessions.

Healio and Cardiology Today have curated a list the most-read news in HF of 2021.

As the COVID-19 pandemic continued to dominate the news, more was learned about its CV implications over the past year. However, the year also featured a number of important developments in other realms of cardiology.

The American Heart Association Scientific Sessions were held virtually Nov. 13 to 15. The event included numerous presentations of new data in cardiology.

Javed Butler, MD, spoke with Healio about results from the EMPEROR-Preserved trial that he presented at the American Heart Association Scientific Sessions.

In this video, Javed Butler, MD discusses research on SGLT2 inhibitors presented at the American Heart Association Scientific Sessions.